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SELECTION OF THE MONTH 
Big Title: “Fibrosis stage predicts mortality in patients with NAFLD” 
 
Small Title:  
The negative liaison between monocytes and NK cells (in HCV infection) 
(Cirrhosis): Factors leading to ACLF in outpatients identified 
 
LIVER INJURY 
Sterile inflammation in hepatic ischemia-reperfusion injury (IRI) 
Hepatic IRI, which is characterized by local inflammation and hepatocellular death, 
represents a risk factor for acute and chronic rejection in liver transplantation. To gain 
new insights into mechanisms underlying hepatic IRI, Nakamura et al. performed 
elegant translational research in human liver transplants and primary murine 
macrophage cultures. They reveal that, in macrophages, a signaling axis involving 
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heme oxygenase 1, NAD-dependent protein deacetylase sirtuin-1, and p53 plays 
a crucial role in the development of hepatic sterile inflammation. This may lead to 
novel therapeutic approaches in patients who receive a liver transplant. 
 
LIVER REGENERATION 
Serotonin: friend of foe? 
Besides its critical role during liver regeneration, serotonin (also as 5-
hydroxytryptamine, 5-HT) is known to be a mitogenic factor in several cancers. 
Padickakudy et al. evaluated whether intra-platelet 5-HT was associated with 
oncological outcome after liver resection and also evaluated its ability to serve as a 
therapeutic target to promote liver regeneration. Their results show for the first time 
that intra-platelet 5-HT is associated with early disease recurrence after liver 
resection in humans. Thus, pharmacological intervention aimed to promote 5-HT-
mediated liver regeneration should be considered with caution. A careful definition of 
indications and timing is needed to promote liver regeneration without inducing 
deleterious effects. 
 
NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) 
NAFLD increases the risk of chronic kidney disease and fibrosis stage predicts 
mortality in NAFLD patients 
NAFLD is a growing cause of chronic liver disease worldwide. Identifying NAFLD 
patients at an increased risk for mortality and liver-specific morbidity is mandatory. In 
this issue, Hagström et al. conducted a retrospective cohort study of 646 biopsy-proven 
NAFLD patients and matched controls. During a follow-up of 20 years, 12% of NAFLD 
patients developed severe liver disease (only 2.2% of controls). The risk of severe 
liver disease increased per stage of fibrosis (HR ranging from1.9 in F0 to 104.9 in 
F4). Similar results were seen for overall mortality. Importantly, the presence of 
NASH did not change these estimates significantly. This important study strongly 
suggests that all patients with NAFLD should undergo non-invasive assessment of the 
stage of liver fibrosis. Preventive and therapeutic maneuvers aimed at attenuating the 
progression of liver fibrosis in NAFLD patients should be implemented. In another 
article in this issue of the Journal, Sinn et al. studied the association between NAFLD 
and chronic kidney disease (CKD) a frequent co-morbidity in patients with metabolic 
syndrome. The authors performed a retrospective cohort study of 41,430 adult men 
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and women without CKD at baseline who underwent repeated health check-up 
examinations. During a median follow-up of 4.15 years, they identified 691 incident 
CKD cases. The risk of CKD increased progressively with increased NAFLD 
severity. The multivariable-adjusted hazard ratios for CKD of participants with a 
NAFLD Fibrosis Score (NFS) ≥ -1.4 was 1.58, suggesting that existence of advanced 
stages of NAFLD predisposes to the development of CKD.  This clinically relevant 
study suggests that NAFLD may adversely affect renal function and may need 
careful attention for an increased risk of CKD. 
 
HEPATITIS C VIRUS (HCV) INFECTION 
Impact of coffee consumption on all-cause mortality in HIV-HCV coinfection, the 
long-term sequelae of the Irish single source HCV outbreak, clinical outcomes 
after delisting from the liver transplant waiting list, the negative liaison between 
monocytes and NK cells  
Polyphenols and caffeine in coffee have several well described hepato-protective 
properties but coffee consumption has been also associated with a 14% risk reduction 
in all-cause mortality in the general population. The study by Carrieri et al. is the first 
to investigate the relationship between coffee consumption and all-cause mortality risk 
in HIV and HCV co-infected patients by using data from a large five-year longitudinal 
follow-up study in the ANRS CO13-HEPAVIH French national cohort of HIV-HCV co-
infected patients. Drinking three or more cups of coffee per day halved all-cause 
mortality risk in HIV-HCV infected patients, and this association remained 
significant even after adjustment for relevant co-factors like severe liver fibrosis, 
and smoking status. Further research will help to better elucidate the causal 
mechanisms of this relationship; but in the meantime, certain at-risk populations like 
HIV-HCV coinfected patients should be aware of these results to adapt their coffee 
drinking behavior individually. 
Between 1977-1979, over 800 women were infected in Ireland with HCV genotype 1b 
via contaminated anti-D immunoglobulin from a single donor. Initially, after 17 years, a 
quite benign course with a low rate of cirrhosis development (2%) was reported in this 
group, but almost 20 years have elapsed since then. Now, approximately 36 years 
after infection, Garvey et al. demonstrated a substantial increase in cirrhosis, 
HCC and liver-related death which doubled in the latest five years of follow-up. 
Although the overall progression rate remains relatively slow in this cohort, nearly every 
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5th patient has now reached a disease state that is probably not any more reversible 
by treatment, and harbors a significant life-time risk for HCC development. This 
happened despite regular medical supervision, highlighting once more the limited 
effect of our previous interferon-based treatment strategies in altering the population-
based HCV-associated morbidity and mortality - a finding that will hopefully change 
when follow-up data will be collected after direct acting antivirals entered the scene.  
Treating patients with HCV-induced decompensated cirrhosis while on the liver 
transplant waiting list offers the chance for delisting due to improvement of liver 
function. The long-term efficiency of this strategy in terms of clinical outcomes, 
however, remains largely unclear. Pascasio et al. further expanded on this important 
issue by following the course of patients treated on the liver transplant waiting list. They 
confirmed that approximately a quarter of the treated patients with 
decompensated disease presented a significant improvement in liver function 
that allowed delisting, and 80% of them remained stable after a median follow-
up of 88 weeks. These results are of high importance as they imply that delisting due 
to improvement in liver function is overall a safe strategy helping to save organs for 
those with the highest transplantation need. However, close monitoring of the delisted 
patients is mandatory given the significant risk of HCC development in this particular 
group. 
Coordination and collaboration between immune cells are essential to fight pathogens 
and the interplay between natural killer (NK) cells and monocytes represents one first-
line of protection from pathogens and takes place during the early stages of innate 
immune responses against them. The authors of the current study have previously 
shown that peripheral blood NK cells from HCV-infected patients fail to upregulate 
TRAIL expression after exposure to HCV, a process accompanied by impaired cytolytic 
potential and Extracellular Signal-Related Kinase 1 (ERK) activity. Now, Mele et al. 
were able to demonstrate that during HCV infection monocytes secrete 
interleukin (IL)-18 and IL-36 inhibitory proteins, reducing NK cell activation, and 
consequently inhibiting their ability to express TRAIL and kill target cells. This 
important study confirms the essential role of monocytes as negative regulators of NK 







Identification of factors associated with development of acute on chronic liver 
failure (ACLF) in outpatients, declining mortality of cirrhotic patients admitted to 
the intensive care units 
Hospitalized cirrhotic patients who develop ACLF have high mortality rates. At present 
it is unclear which patients attending the outpatient department will develop ACLF. The 
paper by Piano et al. addresses this important question. The authors followed 466 
cirrhotic outpatients in a tertiary center for a mean of about 4 years. 118 patients 
developed ACLF during follow up and these patients had a 3-month mortality of 
44%. They identified that the MELD score, mean arterial pressure and 
hemoglobin were independent predictors of ACLF development. These data will 
help stratify patients in the outpatient department at high-risk of developing ACLF so 
that measures to prevent its development can be instituted. 
Previous studies have suggested that the mortality of cirrhotic patients admitted to the 
ICU was higher than non-cirrhotic patients and the incidence was increasing. 
Majumdar et al. describe the results of an important study from Australia, where they 
interrogated the ANZ Intensive Care Society Centre for Outcome and Resource 
Evaluation Adult Patient Database over a 15-year period. They show for the first time 
that although cirrhosis was an independent predictor of mortality, the decline in 
mortality rate observed in non-cirrhotic patients was similar to the cirrhotics. 
They confirm the importance of organ failures in defining the risk of death and 
also show for the first time that risk-adjusted mortality rates were similar in the 
ICU’s of the transplant centers compared with the non-transplant centers. These 
data illustrate the improvement in outcomes possibly due to the greater awareness and 
understanding of organ failures in cirrhosis. 
 
CHOLESTASIS 
Mutations in key genes observed in about 30% patients with cholestasis 
Bile salt exporters, BSEP, ABCB11; multidrug resistance protein 3, MDR3, ABCB4; 
and the ATPase familial intrahepatic cholestasis 1, FIC1, ATP8B1 mediate bile 
formation. Mutations in these genes underlie many cholestatic liver diseases such as 
intrahepatic cholestasis of pregnancy, benign recurrent intrahepatic cholestasis or low 
phospholipid-associated cholelithiasis to progressive familial intrahepatic cholestasis 
but which disorder is associated with which mutation is not known. Droge et al. 
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describe the results of an exciting new study where they included 427 patients 
with various cholestatic diseases and studied the role of these genetic defects. 
They identified that 149-patients carried at least one disease-associated 
mutations. In all, 154 different mutations were identified comprising 25 novel 
ones. These data support the idea that genetic variants can be found in a significant 




Pan-mTOR inhibitor for intrahepatic cholangiocarcinoma 
The mechanistic target of rapamycin (mTOR) coordinates eukaryotic cell growth and 
metabolism with environmental inputs, including nutrients and growth factors. 
Deregulated mTOR signaling is implicated in the progression of cancer. MLN0128, a 
second generation pan-mTOR inhibitor, shows efficacy for several tumor types. 
Intrahepatic cholangiocarcinoma is a cancer without effective treatment options. Zhang 
et al. developed a mouse model of intrahepatic cholangiocarcinoma to assess the 
efficacy of MLN0128 in this cancer. Their findings strongly suggest that mTOR 
inhibitors may be beneficial for the treatment of intrahepatic 
cholangiocarcinoma, even in tumors that are resistant to standard of care 
chemotherapeutics such as gemcitabine-oxaliplatin—based regimen, especially 
in the subset exhibiting activated AKT/mTOR cascade. 
 
HEPATOCELLULAR CARCINOMA (HCC) 
Trunk alterations in early HCC, DDA and HCC risk 
Trunk alterations arise at early stages of cancer and are shared among all malignant 
cells of the tumor. In order to identify trunk alterations in HCC, Torrecilla et al. 
characterized early stages of hepatocarcinogenesis represented by dysplastic nodules 
and small lesions. They show that mutations in TERT (telomerase reverse 
transcriptase), TP53 (tumor protein p53) and CTNNB1 (catenin beta 1) genes 
were the only ones found at this early stage. Analyses in more advanced lesions 
showed that mutations in these same genes were shared between different regions of 
the same tumor and between primary and metastatic tumors, suggesting their trunk 
role in this disease.  
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Risk of HCC occurrence or recurrence following direct-acting antiviral (DAA) HCV 
therapy remains unclear. Waziry et al. aimed to compare the rate of HCC occurrence 
following DAA versus interferon (IFN)-based cure performed a study in patients with 
HCV-related cirrhosis. In addition, they also aimed to compare the rate of HCC 
recurrence following DAA versus IFN-based cure in patients who received curative 
HCC treatment. A search was conducted for reports published between January 2000 
and February 2017. Random effects meta-analyses were undertaken to determine a 
combined estimate of HCC incidence rate per 100/person years. The results show 
no evidence for differential HCC occurrence or recurrence risk following cure 
from DAA and IFN-based therapy. 
 
